XML 41 R32.htm IDEA: XBRL DOCUMENT v3.23.1
Shareholders' Equity (Tables)
3 Months Ended
Mar. 31, 2023
Stockholders' Equity Note [Abstract]  
Summary of comprehensive income (loss)

The following is a summary of comprehensive income (in millions):

 

 

Three Months Ended March 31,

 

 

2023

 

 

2022

 

Consolidated net income

 

$

77.4

 

 

$

62.1

 

Foreign currency translation adjustments

 

 

25.8

 

 

 

(30.5

)

Derivatives designated as hedging instruments, net of tax

 

 

(10.7

)

 

 

21.1

 

Pension liability adjustments, net of tax

 

 

0.1

 

 

 

0.5

 

Comprehensive income

 

 

92.6

 

 

 

53.2

 

Less: Comprehensive income attributable to
   noncontrolling interests

 

 

1.3

 

 

 

0.2

 

Less: Comprehensive loss attributable to redeemable
   noncontrolling interests

 

 

 

 

 

(0.2

)

Comprehensive income attributable to Bruker Corporation

 

$

91.3

 

 

$

53.2

 

Summary of the components of accumulated other comprehensive income (loss), net of tax

The following is a summary of the components of accumulated other comprehensive income (loss) attributable to Bruker Corporation, net of tax (in millions):

 

 

Foreign
Currency
Translation

 

 

Derivatives
Designated as
Hedging
Instruments

 

 

Pension
Liability
Adjustment

 

 

Accumulated
Other
Comprehensive
Income (Loss)

 

Balance at December 31, 2022

 

$

(3.1

)

 

$

4.1

 

 

$

13.8

 

 

$

14.8

 

Other comprehensive income (loss) before
   reclassifications

 

 

25.4

 

 

 

(10.7

)

 

 

0.1

 

 

 

14.8

 

Net current period other comprehensive income (loss)

 

 

25.4

 

 

 

(10.7

)

 

 

0.1

 

 

 

14.8

 

Balance at March 31, 2023

 

$

22.3

 

 

$

(6.6

)

 

$

13.9

 

 

$

29.6

 

 

Schedule of the impact of stock-based compensation expense

The Company recorded stock-based compensation expense as follows in the unaudited condensed consolidated statements of income and comprehensive income (in millions):

 

 

Three Months Ended
March 31,

 

 

2023

 

 

2022

 

Stock options

 

$

0.4

 

 

$

0.4

 

Restricted stock units

 

 

3.7

 

 

 

3.4

 

Employee Stock Purchase Plan

 

 

0.2

 

 

 

 

Total stock-based compensation expense

 

$

4.3

 

 

$

3.8

 

 

 

Three Months Ended
March 31,

 

 

2023

 

 

2022

 

Cost of product revenue

 

$

0.3

 

 

$

0.6

 

Selling, general and administrative

 

 

3.6

 

 

 

2.6

 

Research and development

 

 

0.4

 

 

 

0.6

 

Total stock-based compensation expense

 

$

4.3

 

 

$

3.8